


your partner in drug validation

Leishmaniasis

Leishmania major is a protozoan parasite infecting the skin of humans and rodents. The disease Leishmaniasis affects the populations of 88 counties worldwide and current World Health Organization estimates report 12 million people are infected with an annual incidence of two million. Leishmania can be subdivided into three categories: Cutaneous, Mucosal and Visceral Leishmaniasis. The cutaneous forms of the disease normally produce skin ulcers on the exposed parts of the body such as the face, arms and legs. In mucocutaneous forms of leishmaniasis, lesions can lead to partial or total destruction of the mucous membranes of the nose, mouth and throat cavities and surrounding tissues. Whilst Visceral leishmaniasis is characterized by fever, substantial weight loss, and swelling of the spleen and liver.



Experimental readouts:

- Footpad swelling
- Parasite load and dissemination
- Quantitative PCR analysis of tissue cytokines and chemokines

Duration:

7-140 days dependent upon experimental readouts

Our scientific project managers can provide expert advice and guidance for all of your efficiacy studies.

Please contact us for customized Service Packages info@preclinbiosystems.com

Administration of test compounds

Service Package I

- Pathogen load
- Assessment of swelling at site of infection

Service Package II

Service Package I is available alone, or in combination with Service Packages II and III

Analysis of cellular infiltration and effector function

Service Package III

Quantitative PCR analysis of tissue cytokines and chemokines